OncLive® Launches Scout, an AI Assistant to Help Oncologists Quickly Access Expert Insights
OncLive® Launches Scout, an AI Assistant to Help Oncologists Quickly Access Expert Insights
CRANBURY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- OncLive®, the leading resource for oncology professionals, today formally announced the beta release of Scout, an artificial intelligence-powered assistant developed to streamline access to expert clinical insight and research-based commentary. Scout is accessible on both the desktop and mobile versions of OncLive.com.
First introduced in March as a beta tool, Scout is designed to support oncology clinicians by delivering concise, contextually relevant answers derived from a trusted set of oncology news, research, and multimedia programming. The AI model is trained on an extensive library of expert-driven video discussions from OncLive's signature programs, including Peer Exchange and Insights, to deliver results that are accurate, timely, and rooted in expert opinion.
Scout offers a practical and time-saving utility by synthesizing complex clinical discussions into succinct responses grounded in expert consensus. Each result includes direct reference links and navigational tools that allow users to view the exact segment within a video where a cited opinion or insight was delivered, eliminating the need for manual searching.
'Scout was created with the goal of enhancing clinical efficiency by enabling physicians to access high-quality, peer-informed content in real time,' said Robert Goldsmith, senior vice president of oncology corporate development at MJH Life Sciences®. 'By leveraging OncLive's deep content repository and integrating it with advanced AI capabilities, Scout represents an evolution in how oncology professionals interact with medical information by delivering relevant, expert-based guidance within seconds.'
Designed to fit seamlessly into an oncologist's workflow, Scout provides:
Succinct summaries based on expert video commentary and published articles.
Quick-reference links to related reading and supporting resources.
Direct video navigation to the exact moment an expert delivers their commentary.
Mobile-responsive functionality, optimized for use on the go.
Scout remains in beta as ongoing development and refinement continue in partnership with the oncology community. The platform is actively gathering user feedback to inform enhancements and future iterations. A mobile application is currently in development and is anticipated to be released later this year. Scout is available now on OncLive.com via desktop and mobile browsers.
For more information or to try Scout, visit www.OncLive.com and click the Scout icon in the navigation bar.
About OncLive
The leading digital platform and multichannel resource for practicing oncologists, OncLive offers oncology professionals peer-to-peer insights, news and practical information they can use to offer the best patient care. OncLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
About MJH Life Sciences
MJH Life Sciences is the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels, providing health care professionals with the information and resources they need to optimize patient outcomes. MJH combines the reach and influence of its powerful portfolio of digital and print product lines, live events, educational programs and market research with the customization capabilities of a boutique firm. Clients include world-leading pharmaceutical, medical device, diagnostic and biotech companies. For more information, please visit https://www.mjhlifesciences.com/.
Media Contact:Julia ParadizovaMJH Life Sciencesjparadizova@mjhlifesciences.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42b9afe3-2799-4a09-9a44-51f6c686e108Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
World's First Needle-Free Procedure Targeting Deep Facial Muscles and Skin, EMFACE® by BTL Aesthetics Surpasses 1 Million Global Treatments, Drives Rapid Adoption in Singapore's Aesthetic Market
SINGAPORE, June 10, 2025 /PRNewswire/ -- EMFACE® the groundbreaking non-invasive natural facial lifting treatment developed by BTL Aesthetics (BTL), has surpassed 1 million treatments worldwide within the first two years of its introduction. This global milestone is a testament to EMFACE®'s position as the leading non-invasive aesthetic treatment, leveraging breakthrough technology to invent the first needle-free procedure capable of effectively providing deep facial muscle toning and skin tightening for a more lifted and youthful appearance. Launched in the United States in 2022 and introduced to Singapore in March 2023, the award- winning EMFACE® quickly gained traction among aesthetic practitioners and patients seeking effective non-invasive facial rejuvenation in major markets such as the United States, Europe, Singapore, Japan, Korea and Taiwan. According to various doctors, the demand for non-invasive aesthetic treatments in Singapore continues to rise due to reduced stigma as aesthetic treatments are increasingly viewed as a form of self-care, as reported by Channel News Asia[1]. Additionally, The Straits Times[2] has also highlighted that advancements in technology are providing more convenient solutions with minimal downtime, allowing for more accessible and efficient treatments. "In recent years, we have seen a major shift in what patients are looking for – effective treatments that deliver natural-looking results without needles, surgery, or extended recovery times. Today's consumers are busy and want options that fit seamlessly into their lifestyles, and non-invasive treatments are answering that call," said Dr. Lynn Chiam, Dermatologist at the Children & Adult Skin Hair Laser Clinic. Channel News Asia[1] has also noted that The Ministry of Health (MOH) reported an average increase of 40 new licensed providers offering aesthetic services between 2020 and 2023. As more individuals seek effective and non-invasive options to achieve their desired appearance, this surge reflects the increasing preference for non-invasive treatments like EMFACE®, with demand expected to grow even further. To cater to the growing demand for non-invasive aesthetic treatments, EMFACE® effectively targets the facial elevator muscles for a natural lift in just 20 minutes, with no pain and no downtime. Although tangible results can be seen right after the treatments, a minimum of four sessions can deliver truly optimal results. Additionally, a fully personalized treatment plan can be curated by trusted Aesthetic Providers. EMFACE® is the first device in the market to utilise High-intensity Facial Electrical Stimulation (HIFES) and Synchronized RF technologies. HIFES™ selectively tones the face-elevating muscles to restore and elevate the support of facial features while Synchronized RF heating remodels and smooths the skin by increasing the levels of collagen and elastin fibers. This allows the treatment to penetrate deep into the facial muscles, lifting every layer from muscle to skin, effectively enhancing facial contours from within – a feat previously unattainable with injectables or traditional energy-based devices. EMFACE® has also expanded its capabilities with the introduction of under-eye applicators, making EMFACE® the only treatment available that addresses the root causes of ageing around the eyes non-invasively by toning muscles and tightening skin. The periorbital area is often the first to show signs of ageing with eyebags, crow's feet, and dark circles. While traditional solutions focus primarily on the skin, the new eye applicators further enhance the treatment's effectiveness by uniquely targeting both the lower part of the orbicularis oculi muscle and delicate skin in the periorbital area. As the original muscle toning and skin lifting U.S. FDA-cleared treatment, EMFACE® has been recognized for its innovative technology and revolutionary results, having won the 2025 New Beauty Award for 'Best Non-Invasive Facial Sculptor', the 2023 Northern Ireland Cosmetic Medicine Award for 'Innovative Device of the Year', and the 2023 Cosmopolitan Holy Grail Beauty Award for 'Best Treatment Game Changer'. "BTL Aesthetics is proud of reaching this remarkable milestone which underscores the commitment we have to providing cutting-edge innovative aesthetic solutions. Achieving 1 million EMFACE® treatments globally in under two years highlights the growing consumer demand for non-invasive facial lifting solutions that are painless, require no downtime, and can seamlessly fit into their busy routines," said Mr Ricardo Manaloto, General Manager of BTL Aesthetics. "We are truly heartened by the trust that our valued partner practitioners have placed in EMFACE®. Their recognition of the role that toning facial muscles plays in facial lifting reinforces its importance as a foundational component of any effective facial lifting treatment. Mr. Manaloto added. For more information about EMFACE® and the available trusted providers in Singapore, visit BTL Aesthetics Singapore at [1] Channel News Asia – Youths, seniors embracing aesthetics boom: up/youths-seniors-embracing-aesthetics-boom-4635091 [2] The Straits Times – Social media influencers driving demand for aesthetic treatments in Singapore: About BTL Aesthetics Founded in 1993, BTL has grown to become one of the world's leading medical equipment manufacturers. With 500+ engineers and 3,000+ employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including intimate health and mental wellness. Among other brands, BTL's products include EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, EXOMIND™ as well as their proprietary HIFEM®, HIFES™ and EXOTMS™ procedures. View original content: SOURCE BTL Singapore Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in non-invasive liver diagnostics, and Boehringer Ingelheim, a global biopharmaceutical company, today announced an expansion of their long-standing partnership to change the trajectory of the disease by moving beyond clinical trials to focus on early detection, diagnosis, and access to care. By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next phase of partnership will include: Raising awareness of MASH among patients, healthcare professionals, and policymakers about the urgent need for early screening and diagnosis. Encouraging the adoption of streamlined care pathways by fostering collaboration across healthcare organizations and medical specialties. Expanding awareness and access to non-invasive technologies (NITs), including scientific collaborations to generate evidence relating to NITs in the care of people living with MASH. "For too long, serious liver diseases like MASH have gone under the radar—but with MASH rates soaring alongside the global obesity epidemic, it's time to tackle liver disease head on," said Sandy Sommer, Head of the Therapeutic Area for Cardiovascular, Renal and Metabolic at Boehringer Ingelheim. "Obesity and MASH are deeply interconnected chronic diseases that no organization can tackle alone. At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to drive transformative change in metabolic health for patients, doctors, and healthcare systems worldwide." MASH is a chronic disease that results from excess fat accumulation and inflammation in the liver. It is more common in people living with obesity and, left untreated, can lead to scarring, cirrhosis, and liver failure. Because the disease is often silent in its early stages, it is estimated that fewer than one in five people with MASH are formally diagnosed, underscoring the urgent need for scalable and non-invasive tools to screen these patients and support them with ongoing care. FibroScan®, Echosens' non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim's liver disease research and continues to support two ongoing Survodutide Phase III trials by screening and monitoring patients; as a non-invasive test, FibroScan® offers a fast, painless, cost-effective, and scalable alternative to liver biopsy. Survodutide combines GLP-1 and glucagon receptor agonists as a novel potential treatment for MASH and associated metabolic conditions like obesity. Survodutide is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal and metabolic disease areas. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. "We are excited to expand our collaboration with Boehringer Ingelheim, whose innovative approach has the potential to further advance the treatment landscape for MASH," said Dominique Legros, CEO of Echosens. "This partnership reflects our ongoing commitment to support the global liver disease community by enabling smarter clinical trials and broader access to non-invasive diagnostic tools. We are proud to collaborate with Boehringer Ingelheim and welcome them into our shared mission to improve liver health outcomes." About Echosens Pioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 5,384 peer-reviewed publications and 218 international guidelines. Echosens has made FibroScan® available in over 127 countries, enabling millions of liver examinations worldwide. About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. View original content: SOURCE Echosens Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Cognex Introduces OneVision: A Breakthrough Cloud Platform for AI-Powered Machine Vision
New Training Environment Delivers Scalable Automation and Solves Key Barriers to Industrial AI Adoption NATICK, Mass., June 10, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, today announced the upcoming full launch of OneVision™, a cloud-based platform that will transform how manufacturers build, train, and scale AI-powered vision manufacturers build, train, and scale AI-powered vision applications. "OneVision is the result of nearly a decade of industrial AI innovation at Cognex. By combining our advanced AI technology with excellent customer experience, we continue to unlock new possibilities for our customers," said Carl Gerst, Executive Vice President of Vision and ID Products at Cognex. "We're simplifying the entire application development process; helping our customers move faster, scale more efficiently, and maximize the value of their automation investments." Designed for the demands of global manufacturing, OneVision tackles the most common barriers to wide-scale deployment of AI-powered machine vision: Long development cycles and steep learning curves: An intuitive interface with guided workflows allows teams of all skill levels to shorten setup time from months to minutes. Expensive infrastructure investments: Cloud-based delivery eliminates the need for additional hardware, lowering upfront costs and maximizing ROI. Lack of integration and disconnected operations: A unified platform brings tools, data, and workflows together to streamline collaboration, leverage shared work, and accelerate deployment across devices, lines, and locations. Inconsistent performance across sites: Centralized development combined with local customization ensures standardization while providing flexibility for site-specific requirements. With the OneVision software platform, Cognex expands its industry-leading portfolio of machine vision products, unlocking new applications, accelerating AI adoption, and allowing users to solve complex vision tasks faster, more reliably, and at scale. OneVision is currently available to select customers on the In-Sight® 3800 and 8900 vision systems and will be released on additional Cognex products in early 2026. and will be released on additional Cognex products in early 2026. About Cognex Corporation For over 40 years, Cognex has been making advanced machine vision easy, paving the way for manufacturing and distribution companies to get faster, smarter, and more efficient through automation. Innovative technology in our vision sensors and systems solves critical manufacturing and distribution challenges, providing unparalleled performance for industries from automotive to consumer electronics to packaged goods. Cognex makes these tools more capable and easier to deploy thanks to a longstanding focus on AI, helping factories and warehouses improve quality and maximize efficiency without needing highly technical expertise. We are headquartered near Boston, USA, with locations in over 30 countries and more than 30,000 customers worldwide. Learn more at IR ContactGreer AvivHead of Investor RelationsCognex Corporationir@ Media ContactJeremy SaccoSenior Manager, Global Content MarketingCognex Corporationpr@ SOURCE Cognex Corporation Sign in to access your portfolio
